This study is the spatial transcriptomic approach for revealing the resistance mechanism of trastuzumab deruxtexan in HER2 positive breast cancer patients.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
SCREENING
Masking
NONE
Enrollment
50
1. List of HER2 positive breast cancer * Stage IV disease * Treated with T-Dxd * Available FFPE samples 2. Prepare tissue for digital spatial proteomics * FFPE/H\&E slide * Region of Interest(ROI) check * Make a Tissue microarray * Prepare special slide for GeoMx 3. GeoMx data analysis with clinical outcome
Ji-Yeon Kim
Seoul, South Korea
RECRUITINGSpatial transcriptomic analysis
Protein expression and relationship protein-protein in HER2 positive breast cancer tumor cells and tumor microenvironment.
Time frame: Before chemotherapy, curative surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.